An FDA committee recommended the composition of influenza vaccines for the 2025-2026 season in the US based on a review of data on circulating viruses from the US and worldwide monitoring.[1][2] The recommendations were issued by an interagency team of experts from the FDA, CDC, and Department of Defense.[1][2] The strains proposed for trivalent egg-based vaccines are: A/Victoria/4897/2022 (H1N1)pdm09-like virus, A/Croatia/10136RV/2023 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria lineage)-like virus.[1][2] For trivalent cell-based or recombinant vaccines, the following are recommended: A/Wisconsin/67/2022 (H1N1)pdm09-like virus, A/District of Columbia/27/2023 (H3N2)-like virus, and B/Austria/1359417/2021 (B/Victoria lineage)-like virus.[1][2] These recommendations are similar to last year's selection and do not include quadrivalent vaccines.[1][2] The FDA expects a sufficient and diverse supply of vaccines without delays in availability to the public.[1][2] The decision was based on data on circulating viruses, vaccine effectiveness from mid-season 2024-2025, and candidate viruses for production.[2]